Staphylococcus haemolyticus, a key species of the Staphylococcus genus, holds significant importance in healthcare-associated infections, due to its notable resistance to antimicrobials, like methicillin, and proficient biofilms-forming capabilities. This coagulase-negative bacterium poses a substantial challenge in the battle against nosocomial infections. Recent research has shed light on Staph. haemolyticus genomic plasticity, unveiling genetic elements responsible for antibiotic resistance and their widespread dissemination within the genus. This review presents an updated and comprehensive overview of the clinical significance and prevalence of Staph. haemolyticus, underscores its zoonotic potential and relevance in the one health framework, explores crucial virulence factors, and examines genetics features contributing to its success in causing emergent and challenging infections. Additionally, we scrutinize ongoing studies aimed at controlling spread and alternative approaches for combating it.

Background: Touchscreens are usually microbially contaminated and can therefore act as fomites inside and outside healthcare environments. Due to the increasing use of such touchscreens and the growing awareness of infection risks, approaches that allow safe and automatic disinfection are desired. Ultraviolet (UV) irradiation, with its known antimicrobial efficacy, could achieve this goal, but should be executed with limited touchscreen degradation, disinfection duration, and energy consumption. It should also pose as little harm as possible to humans even in case of failure. Materials and methods: A literature search was performed first to identify the microorganisms most commonly found on touchscreens. Then, the 90% reduction doses (D90 doses) for the different relevant microorganisms and UV spectral ranges were determined from the literature, and irradiation doses are suggested that should reduce most of these important microorganisms by 5 log-levels. Results: The most frequent microorganisms are staphylococci, bacilli, micrococci, enterococci, pseudomonads and E. coli with small differences between hospital and community environments, if antibiotic resistance properties are ignored. The determined irradiation doses for a 5 log-reduction of the most frequent microorganisms are about 40 mJ/cm2, 80 J/cm2, 500 J/cm2 and 50 mJ/cm2 for the UV spectral ranges UVC, UVB, UVA and far-UVC, respectively. These doses are also sufficient to inactivate all nosocomial ESKAPE pathogens on touchscreens by at least 99.999%. Conclusion: Disinfection is achievable in all UV spectral ranges, with UVC being the most effective, enabling automatic disinfection within a minute or less. The much higher doses required in the UVB and UVA spectral range result in much longer disinfection durations, with the advantage of a reduced risk to humans. For all kinds of UV irradiation, the doses should be limited to reasonable values to avoid irradiating an already more or less sterile surface and to prevent degradation of touchscreen devices.
Hintergrund: Touchscreens weisen meist mikrobielle Kontaminationen auf, die innerhalb und außerhalb von Gesundheitseinrichtungen zu Infektionen führen können. Aufgrund des zunehmenden Einsatzes von Touchscreens und des wachsenden Hygiene-Bewusstseins werden Ansätze gesucht, die eine sichere und möglichst automatische Desinfektion ermöglichen. Ultraviolette (UV) Bestrahlung mit ihrer bekannten antimikrobiellen Wirkung könnte dieses Desinfektionsziel erreichen, doch sollte dies mit einer sinnvollen Begrenzung der Touchscreen-Degradation, der Desinfektionsdauer und des Energieverbrauchs erfolgen und auch im Fehlerfall Menschen möglichst wenig schädigen. Material und Methoden: Zunächst wird eine Literaturrecherche durchgeführt, um die am häufigsten auf Touchscreens vorkommenden Mikroorganismen zu identifizieren. Dann werden die 90%- Reduktionsdosen (D90-Dosen) für die verschiedenen Mikroorganismen und UV-Spektralbereiche aus der Literatur ermittelt und Bestrahlungsdosen vorgeschlagen, die die meisten der relevanten Mikroorganismen um 5 Log-Stufen reduzieren. Ergebnisse: Die am häufigsten gefundenen Mikroorganismen sind Staphylokokken, Bazillen, Mikrokokken, Enterokokken, Pseudomonaden und E. coli mit geringen Unterschieden zwischen Gesundheitseinrichtungen und nicht-medizinischen Umgebungen, wenn Antibiotikaresistenzen nicht betrachtet werden. Die ermittelten Bestrahlungsdosen für eine 5 Log-Reduktion der häufigsten Mikroorganismen liegen bei etwa 40 mJ/cm2, 80 J/cm2, 500 J/cm2 und 50 mJ/cm2 für die UV-Spektralbereiche UVC, UVB, UVA bzw. Far-UVC. Diese Dosen reichen auch aus, um alle nosokomialen ESKAPE-Erreger auf Touchscreens um mindestens 99,999% zu inaktivieren.Schlussfolgerung: Eine Desinfektion ist in allen UV-Spektralbereichen möglich, wobei UVC am wirksamsten ist und eine automatische Desinfektion innerhalb einer Minute oder weniger ermöglicht. Die viel höheren benötigten Dosen im UVB- und UVA-Spektralbereich führen zu einer deutlich längeren Desinfektionsdauer mit dem Vorteil eines geringeren Risikos für den Menschen. Bei allen Arten der UV-Bestrahlung sollten die Dosen auf vernünftige Werte begrenzt werden, um die Bestrahlung einer bereits mehr oder weniger sterilen Oberfläche zu vermeiden und um die Degradation von Touchscreen-Geräten zu minimieren.

Abstract  Skin disease associated with the cutaneous commensal organisms Staphylococcus intermedius, Malassezia pachydermatis and Demodex canis is frequently encountered in veterinary medicine. In treatment the aim is elimination of the commensal, but recurrence of skin disease is not unusual. In this review, these potentially pathogenic commensals and their ecology are discussed with particular reference to skin biology and the surface ecosystem. The strategies employed by the micro-organisms for survival and the defence mechanisms of the host are considered. Disease occurs when the virulence of the commensal overwhelms the resistance of the host. It is hoped that an understanding of the complex nature of the skin and its commensals will lead to a better understanding of those diseases associated with commensals and in consequence more effective treatment. Résumé- Les dermatoses associées aux organismes commensaux cutanés Staphylococcus intermedius, Malassezia pachydermatis et Demodex canis sont fréquentes en médecine vétérinaire. Le traitement vise àéliminer le commensal, mais les récidives sont fréquentes. Dans cet article, les commensaux potentiellement pathogènes et leur écologie sont discutés avec une référence particulière à la biologie cutanée et à l\'écosystème de surface. Les stratégies employées par les microorganismes pour survivre et les mécanismes de défense de l\'hote sont présentés. La pathologie se développe lorsque la virulence du commensal outrepasse la résistance de l\'hote. Il faut espérer que la compréhension de la nature complexe de la peau et de ses commensaux, permettent une meilleure compréhension des pathologies associées à ces commensaux et par conséquent un traitement plus efficace. [Mason, I. S., Mason, K. V., Lloyd, D. H. A review of the biology of canine skin with respect to the commensals Staphylococcus intermedius, Demodex canis and Malassezia pachydermatis (Une revue de la biologie de la peau concernant les commensaux Staphylococcus intermedius, Demodex canis et Malassezia pachydermatis). Veterinary Dermatology 1996; 7: 119-132.] Resumen  En medicina veterinaria son frecuentes las dermatopatías asociadas a los microorganismos comensales Staphylococcus intermedius, Demodex canis y Malassezia pachydermatis. El tratamiento busca la eliminatión del comensal, aunque no son raras las recidivas. En esta revisión se discute la ecología de estos comensales potencialmente patógenos, con especial énfasis en la biologia cutánea y el ecosistema superficial. Se tienen en cuenta las estrategias para la supervivencia utilizadas por los microorganismos y los mecanismos de defensa del huésped. La enfernedad se desarrolla cuando la virulencia del comensal supera la resistencia del huésped. Se espera que el mejor conocimiento de la naturaleza compleja de la piel y de sus comensales llevará a un mejor conocimiento de las enfermedades asociadas a los comensales y, consecuentemente, a un tratamiento más efectivo. [Mason, I. S., Mason, K. V., Lloyd, D. H. A review of the biology of canine skin with respect to the commensals Staphylococcus intermedius, Demodex canis and Malassezia pachydermatis (Revision de la biologia cutánea con respecto a los comensales Staphylococcus intermedius, Demodex canis y Malassezia pachydermatis). Veterinary Dermatology 1996; 7: 119-132.] Zusammenfassung- Hauterkrankungen in Verbindung mit den kutanen, kommensalen Organismen Staphylococcu intermedius, Malassezia pachydermatis und Demodex canis werden in der Veterinärmedizin häufig angetroffen. Das Ziel der Behandlung ist die Elimination der Kommensalen, aber die Rezidivierung der Hauterkrankung ist nicht ungewöhnlich. In dieser Übersicht werden diese potentiell pathogenen Kommensalen und ihre Ökologie mit speziellem Bezug zur Biologie der Haut und des Ober-flächenökosystems diskutiert. Die Überlebensstrategien dieser Mikroorganismen und die Abwehrmechanismen des Wirtes werden berücksichtigt. Eine Erkrankung tritt auf, wenn die Virulenz des Kommensal die Widerstandskraft des Wirtes übertrifft. Man hofft, daß das Verstehen der komplexen Natur der Haut und ihrer Kommensalen zum besserem Verständnis dieser mit den Kommensalen verbundenen Krankheiten und damit in der Folge zu wirksamerer Behandlung führt. [Mason, I.S., Mason, K.V., Lloyd, D.H. A review of the biology of canine skin with respect to the commensals Staphylococcus intermedius, Demodex canis and Malassezia pachydermatis (Übersicht über die Biologie der Haut des Hundes mit Berücksichtigung der Kommensalen Staphylococcus intermedius, Demodex canis und Malassezia pachydermatis). Veterinary Dermatology 1996; 7: 119-132.].

UNASSIGNED: To report antibiotic resistance rates and trends of common ocular isolates collected over a 15-year period.
UNASSIGNED: We collected 3533 isolates from July 1, 2005 to July 31, 2020. Antibiotic sensitivity was determined according to the guidelines of the Clinical and Laboratory Standards Institute. Chi-squared (χ 2) test was used to analyze changes in antibiotic susceptibility over 15 years.
UNASSIGNED: Among the 3533 isolates, the predominant pathogens were the staphylococcal species. Methicillin resistance was observed in 381 Staphylococcus aureus (S. aureus) isolates (46.4%) and 1888 coagulase-negative staphylococci (CoNS) isolates (61.1%), and methicillin-resistant (MR) isolates had a high probability of concurrent resistance to fluoroquinolones and aminoglycosides. The mean percentage of resistance in staphylococcal isolates did not reach statistical significance across patient age groups (P = 0.87). Methicillin resistance did not increase in the CoNS (P = 0.546) isolates, and resistance to methicillin slightly decreased among S. aureus (P = 0.04) isolates over 15 years. Additional exploratory analysis revealed a small decrease in resistance to tobramycin (P = 0.01) and chloramphenicol (P < 0.001) among the CoNS isolates. All staphylococcal isolates were susceptible to vancomycin.
UNASSIGNED: Staphylococci were the most common microorganisms responsible for causing ocular infections. Antibiotic resistance was high among staphylococci, with nearly half of these isolates were resistant to methicillin and these had a high probability of concurrent resistance among MR staphylococci to other antibiotics. Overall, ocular resistance did not significantly change during the 15-year study period. We conclude that continued surveillance of antibiotic resistance provides critical data to guide antibiotic selection.

Dalbavancin is a long-lasting lipoglycopeptide active against Gram-positive bacteria, especially methicillin-resistant staphylococci. Few data are available on dalbavancin use for treatment of prosthetic joint infections (PJIs). We describe a cohort of patients treated for PJI with dalbavancin and review the literature regarding this condition.
All adult patients with PJI from the French dalbavancin national cohort from 1 June 2017 to 1 January 2019 were included. We collected clinical and microbiological characteristics and outcome through a standardised questionnaire. Clinical cure was defined as absence of clinical signs of infection at last visit. Failure was a composite criterion defined by persistence or reappearance of signs of infection, and/or switch to suppressive antibiotic treatment and/or death from infection. The literature review was performed using PubMed.
Seventeen patients were included. Bacteria were identified in 16 cases: Staphylococcus aureus (n = 10), including methicillin-resistant S. aureus (n = 1); and coagulase-negative staphylococci (n = 10), including methicillin-resistant Staphylococcus epidermidis (n = 4). Sixteen patients (94.1%) had received antibiotic therapy prior to dalbavancin use (mean of 2.2 ± 1.3 lines). Clinical cure was achieved in 8/17 patients after a median follow-up of 299.0 (IQR 97.0-476.0) days. We reviewed all cases of PJI treated with dalbavancin available in the literature and the overall clinical cure was estimated at 73.1%.
Our study and literature data suggest that use of dalbavancin in PJI could be considered, even as salvage therapy. Dalbavancin appears to be a safe and easy treatment for patients with staphylococcal PJIs.

Infective endocarditis is one of the most difficult-to-treat infectious diseases.
We restricted this review to the anti-infective treatment of the main bacteria responsible for infective endocarditis, i.e. staphylococci, streptococci, enterococci, and Gram-negative bacilli, including HACEK. Specific topics of major interest in treatment strategy are covered as well, including empirical treatment, oral switch, and treatment duration. We searched in the MEDLINE database to identify relevant studies, trials, reviews, or meta-analyses until May 2020.
The use of aminoglycosides for the treatment of endocarditis has been dramatically reduced over the last 20 years. It should be administered once daily, and no longer than 2 weeks. For staphylococcal endocarditis, recent data reinforced the role of anti-staphylococcal penicillins, for methicillin-susceptible isolates (alternative, cefazolin), and vancomycin for methicillin-resistant isolates (alternative, daptomycin). For staphylococcal prosthetic-valve endocarditis, these treatments will be reinforced by the addition of gentamicin during the first 2 weeks, and rifampin throughout the whole treatment duration, i.e. 6 weeks. The optimal duration of antibacterial treatment is 4 weeks for most native valve endocarditis, and 6 weeks for prosthetic-valve endocarditis. The oral switch is safe in patients stabilized after the initial intravenous course.

Ceftriaxone is an empirical antibiotic commonly used to treat pneumonia. However, its use to treat infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) is controversial given limited evidence of its clinical efficacy. The objective of this study was to compare the clinical efficacy of ceftriaxone with either ceftaroline or ceftobiprole in the treatment of pneumonia caused by MSSA. A systematic review and meta-analysis of randomised controlled trials (RCTs) comparing clinical cure in patients with pneumonia who received ceftriaxone versus those who received either ceftaroline or ceftobiprole was conducted. Patients who received ceftriaxone plus vancomycin were excluded. The PubMed, Embase and Cochrane Library databases as well as clinical trial registries were searched up to 8 June 2018. Risk differences (RDs) with 95% confidence intervals (CIs) were estimated using a random-effects model and assessing for heterogeneity (I2). A total of five RCTs met the inclusion criteria; four used ceftaroline and one used ceftobiprole. Four studies included adults and one included paediatric patients. The adult studies included non-intensive care unit patients with mild-to-moderate community-acquired pneumonia. Clinical cure was statistically lower with ceftriaxone (RD, -28.5%, 95% CI -53.5% to -3.4%; P = 0.026; I2 = 16.321%) than with ceftaroline or ceftobiprole. In conclusion, ceftriaxone use was associated with higher clinical failure of MSSA pneumonia compared with ceftaroline or ceftobiprole. This supports the notion that ceftriaxone is not an ideal agent for the treatment of MSSA infections and adds new evidence against its use for MSSA pneumonia.